open access

Vol 4, Supp. B (2013)
Case report
Published online: 2013-10-25
Get Citation

Major molecular response achieved on the third-line nilotinib therapy in a patient with chronic myelogenous leukemia in chronic phase with suboptimal response to imatinib and dasatinib

Tomasz Sacha

open access

Vol 4, Supp. B (2013)
CASE REPORTS
Published online: 2013-10-25

Abstract

Non-hematological toxicity of dasatinib could result from low selectivity against bcr/abl1 kinase and inhibition of additional pathways related to SRC kinase family. The case of patient with chronic myelogenous leukemia in chronic phase treated with imatinib (IM) for loss of complete cytogenetic response achieved after autologous hemopoietic stem cell transplantation is described. Dasatinib was administered as the second line treatment due to resistance to IM. After 7 years of therapy with dasatinib a major molecular response (MMR) has not been achieved, furthermore two episodes of pleural effusion occurred, which were the reason for permanent treatment discontinuation. After resolution of pleural effusion nilotinib in dose of 400 mg twice a day have been introduced. The MMR have been achieved after 9 months of treatment.

Abstract

Non-hematological toxicity of dasatinib could result from low selectivity against bcr/abl1 kinase and inhibition of additional pathways related to SRC kinase family. The case of patient with chronic myelogenous leukemia in chronic phase treated with imatinib (IM) for loss of complete cytogenetic response achieved after autologous hemopoietic stem cell transplantation is described. Dasatinib was administered as the second line treatment due to resistance to IM. After 7 years of therapy with dasatinib a major molecular response (MMR) has not been achieved, furthermore two episodes of pleural effusion occurred, which were the reason for permanent treatment discontinuation. After resolution of pleural effusion nilotinib in dose of 400 mg twice a day have been introduced. The MMR have been achieved after 9 months of treatment.
Get Citation

Keywords

chronic myelogenous leukemia, tyrosine kinase inhibitors, non-hematological toxicity, pleural effusions, dasatinib, nilotinib in third-line treatment

About this article
Title

Major molecular response achieved on the third-line nilotinib therapy in a patient with chronic myelogenous leukemia in chronic phase with suboptimal response to imatinib and dasatinib

Journal

Hematology in Clinical Practice

Issue

Vol 4, Supp. B (2013)

Article type

Case report

Pages

1-3

Published online

2013-10-25

Keywords

chronic myelogenous leukemia
tyrosine kinase inhibitors
non-hematological toxicity
pleural effusions
dasatinib
nilotinib in third-line treatment

Authors

Tomasz Sacha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.